Gerard Brophy - 20 May 2022 Form 4 Insider Report for Avantor, Inc. (AVTR)

Role: EVP, Biopharma Production
Signature: /s/ Scott Baker, as Attorney-in-Fact
Issuer symbol: AVTR
Transactions as of: 20 May 2022
Transactions value $: -$612,986
Form type: 4
Filing time: 23 May 2022, 16:46:26 UTC
Previous filing: 19 May 2022
Next filing: 04 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVTR	Common Stock	Sale	-$613K	-19.6K	-16.82%	$31.27	96.9K	20 May 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.14 to $31.39, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.

Content

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.14 to $31.39, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.